BLU - Bellus Health - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.557B

Cash

313M

Avg Qtr Burn

-22.3M

Short % of Float

7.22%

Insider Ownership

10.26%

Institutional Own.

90.41%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BLU-5937 (P2X3 antagonist) Details Chronic cough	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-5937 (P2X3 antagonist) Details Chronic pruritus, Atopic pruritus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.